Published in An Bras Dermatol on June 18, 2014
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2009) 2.21
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis (2009) 1.71
Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol (2004) 1.68
Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc (1978) 1.62
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol (2008) 1.54
Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol (2007) 1.46
Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol (2007) 1.33
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol (2011) 0.99
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol (2011) 0.90
Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol (2011) 0.81
Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol (2010) 0.80
Switching biologics for psoriasis. Br J Dermatol (2010) 0.80
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol (2010) 0.80
An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. J Drugs Dermatol (2011) 0.79
Multicenter study for efficacy and safety evaluation of a fixeddose combination gel with adapalen 0.1% and benzoyl peroxide 2.5% (Epiduo® for the treatment of acne vulgaris in Brazilian population. An Bras Dermatol (2015) 0.79
Piezogenic Pedal Papules. An Bras Dermatol (2015) 0.75
T-cell-predominant lymphoid hyperplasia in a tattoo. An Bras Dermatol (2014) 0.75